Wealth Enhancement Advisory Services
UTHR icon

Wealth Enhancement Advisory Services’s United Therapeutics UTHR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.15M Sell
16,933
-429
-2% -$242K 0.01% 890
2026
Q1 		$6.64M Buy
17,362
+2,391
+16% +$1.19M 0.01% 761
2025
Q4 		$7.62M Buy
14,971
+8,278
+124% +$3.86M 0.01% 807
2025
Q3 		$3.06M Buy
6,693
+609
+10% +$205K ﹤0.01% 1202
2025
Q2 		$1.79M Buy
6,084
+2,655
+77% +$793K ﹤0.01% 1409
2025
Q1 		$1.06M Sell
3,429
-2,214
-39% -$759K ﹤0.01% 1570
2024
Q4 		$1.99M Buy
5,643
+769
+16% +$283K ﹤0.01% 1198
2024
Q3 		$1.75M Buy
4,874
+2,208
+83% +$746K ﹤0.01% 1125
2024
Q2 		$849K Buy
2,666
+81
+3% +$21.4K ﹤0.01% 1356
2024
Q1 		$594K Buy
2,585
+1,191
+85% +$269K ﹤0.01% 1480
2023
Q4 		$307K Buy
1,394
+149
+12% +$34.3K ﹤0.01% 1796
2023
Q3 		$281K Buy
+1,245
New +$287K ﹤0.01% 1780

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Wealth Enhancement Advisory Services's UTHR Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its United Therapeutics (UTHR) stake by 2.5% in Q2 2026, selling an estimated $242K and leaving 16,933 shares worth $6.15M. The position accounts for 0.01% of the portfolio, ranked #890.

Wealth Enhancement Advisory Services first reported a position in UTHR in Q3 2023 and has held it in 12 quarters since. The position peaked at $7.62M in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Wealth Enhancement Advisory Services held 16,933 shares of United Therapeutics worth $6.15M as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 429 United Therapeutics shares in Q2 2026, an estimated $242K.
  • United Therapeutics made up 0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #890 holding.
  • Wealth Enhancement Advisory Services first reported a position in United Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's United Therapeutics position peaked at $7.62M in Q4 2025.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.